Skip to main content

Day: March 24, 2021

COFACE SA: Declan Daly is appointed Group Chief Operating Officer of Coface

Paris, 24th March 2021 – 07:30 Declan Daly is appointed Group Chief Operating Officer of Coface Coface is pleased to announce that Declan Daly has been appointed Chief Operating Officer of the Coface Group, effective as of April 1, 2021. He will continue to report directly to Xavier Durand, the Coface Group’s Chief Executive Officer, and will join the Group’s Executive Committee. In this newly created role, Declan will be responsible for furthering and accelerating Coface’s transformation terms of service quality and operational efficiency across the Group. This role is a part of Coface’s “Build to Lead” strategic plan. Building on Coface’s previous “Fit to Win” strategic plan, Build to Lead focuses on operational efficiency and customer service quality. The objective of this plan, launched in February 2020, is...

Continue reading

COFACE SA : Declan Daly est nommé Directeur des opérations du Groupe Coface

Paris, le 24 mars 2021 – 07h30 Declan Daly est nommé Directeur des opérations du Groupe Coface Declan Daly est nommé Directeur des opérations du Groupe Coface à compter du 1er avril. Il continuera de reporter directement à Xavier Durand, Directeur Général de Coface et rejoindra le comité de direction du Groupe. Dans cette fonction nouvellement créée, Declan sera chargé de poursuivre et accélérer la transformation de Coface en matière de qualité de service et d’efficacité opérationnelle à travers le groupe. Portés par le précédent plan stratégique de Coface, Fit to Win, l’efficacité opérationnelle et la qualité de service aux clients restent au cœur du plan stratégique actuel, Build to Lead, mis en œuvre par le groupe en Février 2020. L’objectif de ce plan est de positionner Coface comme l’acteur de référence du secteur de l’assurance-crédit,...

Continue reading

Ovaro Kiinteistösijoitus panostaa vuokrauspalveluun

Ovaro Kiinteistösijoitus Oyj  Lehdistötiedote 24.03.2021 klo 8.30 Ovaro Kiinteistösijoitus panostaa vuokrauspalveluun Ovaro Kiinteistösijoitus panostaa vuokrauspalveluunsa ja ryhtyy oman henkilökunnan voimin aktiiviseen asuntojen vuokranvälitykseen. Uudessa vuokrausmallissa Ovaron vuokraustiimi vastaa 1.4.2021 alkaen noin tuhannen asunnon vuokrauksesta. Lisäksi noin 200 erikseen sovittua asuntoa annetaan vuokravälitykseen OVV Asuntopalvelut -ketjulle. Uudistuksen tavoitteena on pienentää ulkopuolisille palveluntarjoajille maksettavien vuokravälityspalkkioiden määrää sekä tehostaa Ovaron toimintaa. ”Olemme onnistuneet nostamaan Ovaron asuntojen vuokrausastetta ja haluamme positiivisen kehityksen jatkuvan. Järjestelyn myötä pääsemme lähemmäksi asiakasta kustannustehokkain keinoin”, sanoo toimitusjohtaja Marko Huttunen. ”Toiminnasta tulee...

Continue reading

Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)

Disease control rate of 79% with one complete response Consistent safety and tolerability profile Study continues with topline results expected in H1 2022Basel, Switzerland, March 24, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today positive results of a pre-planned interim analysis in cohort 2 of the phase 2 study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors), which is assessing the anti-tumor efficacy of the orally administered fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, in patients with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA), a form of bile duct cancer.1 After cohort 1 of the study provided the clinical proof of concept for derazantinib monotherapy in the treatment of iCCA patients with FGFR2 gene fusions, cohort 2 is enrolling iCCA patients...

Continue reading

Basilea berichtet positive Interim-Ergebnisse für Phase-2-Studie FIDES-01 mit Derazantinib bei Patienten mit Gallengangkrebs (iCCA) mit Mutationen oder Amplifikationen des FGFR2-Gens

79 % Krankheitskontrollrate („Disease Control Rate“), einschliesslich einem Patienten mit vollständigem Ansprechen Konsistentes Sicherheits- und Verträglichkeitsprofil Studie wird weitergeführt; Topline-Ergebnisse werden im ersten Halbjahr 2022 erwartetBasel, 24. März 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute positive Ergebnisse einer vorab geplanten Interim-Analyse für die Kohorte 2 der Phase-2-Studie FIDES-01 (engl. Akronym für Fibroblast growth factor Inhibition with DErazantinib in Solid tumors) bekannt. In dieser Studie wird die Antitumor-Wirkung des oral verabreichten Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR) Inhibitors Derazantinib bei Patienten mit inoperablen oder fortgeschrittenem intrahepatischem Cholangiokarzinom (engl. iCCA), einer Form von Gallengangkrebs, untersucht.1 Nachdem in der Kohorte 1 der klinische...

Continue reading

SMCP – 2020 FY Results

2020 Full Year ResultsPress Release – Paris, March 24th, 2021 FY 2020 results impacted by Covid-19Strong execution on cost savings to mitigate the effects: €179.6m of adj. EbitdaSales down -22.9% as reported to €873.0 million; -23.9% on an organic basis Sharp recovery in Mainland China from H2 2020; +3.4%1 in 2020 (o/w +24.5%1 in H2 2020) Strong performance in Digital: +27.6%2 of sales growth Solid execution of Covid-19 action plan: more than €100 million of cost savings3 Net income at -€39.6 excluding Goodwill and right of use impairments Free Cash Flow at €8.0m of which €64.7m in H2 2020 Solid liquidity headroom at the end of the year: > €220m including undrawn RCF          Commenting on the report, Daniel Lalonde, SMCP’s Chief Executive Officer, stated: “As expected, our full year results were strongly impacted by the pandemic which...

Continue reading

SMCP – Résultats annuels 2020

Résultats annuels 2020Communiqué – Paris, le 24 mars 2021 Résultats annuels 2020 impactés par la Covid-19Bonne exécution du plan d’économies pour limiter les effets de la crise : Ebitda ajusté de 179.6 M€Chiffre d’affaires en baisse de -22,9% en données publiées à 873,0M€ ; -23,9% en organique Forte reprise en Chine continentale au S2 2020 ; +3,4%1 en 2020 (dont +24,5%1 au S2 2020) Forte performance du e-commerce : +27,6%2 de croissance des ventes Très bonne exécution du plan d’actions Covid-19 : plus de 100 M€ d’économies3 Résultat net à -39,6 M€ en excluant les dépréciations d’actifs et des droits d’utilisation Free Cash-Flow de 8,0M€ dont 64,7 M€ au S2 2020 Solide flexibilité financière en fin d’année : plus de 220 M€ en incluant la ligne RCF non tirée          Daniel Lalonde, Directeur Général de SMCP a déclaré : « Comme attendu,...

Continue reading

Cornish Metals Receives Permit for United Downs Drilling Programme

VANCOUVER, British Columbia, March 24, 2021 (GLOBE NEWSWIRE) — Cornish Metals Inc. (TSX-V/AIM:CUSN) (“Cornish Metals” or the “Company”), is pleased to announce it will commence an exploration drilling programme at its United Downs project in Cornwall UK, on April 6, 2021, after receiving confirmation of its permitted development rights.The aim of the drill programme is to follow-up on the discovery of high-grade copper-tin mineralisation in drill hole GWDD-002 that recorded 14.69 metres (“m”) at 8.45% copper (“Cu”) and 1.19% tin (“Sn”), as first reported on April 6, 2020; Cornwall Council, being the relevant Mineral Planning Authority, has confirmed Cornish Metals’ permitted development rights enabling the Company to commence an exploration drilling programme at its United Downs prospect under the provisions of Part 17 Class K...

Continue reading

Mowi ASA: Integrated Annual Report 2020

Mowi has today published its 2020 Integrated Annual Report, including sustainability reporting and complete 2020 annual accounts with notes. The integrated report is attached and also available on www.mowi.com/investors/reports/ In connection with Mowi’s EUR 200 million Green Bond issued in January 2020 we are pleased to announce that the first Green Bond Impact Report has been published today and is available on our website www.mowi.com/investors/share-and-bond/bonds/ This information is subject to the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act. AttachmentMowi 2020 AR

Continue reading

Power Coin Will Be Listed on CoinGecko, CoinMarketCap, And Stex

Power Corp, an innovative Finance 3.0 company is excited to announce that its cryptocurrency PowerCoin (PKoin) will be listed on a few reputed Cryptocurrency analysis and exchange listing platforms. PowerCorp is working on a project backed by blockchain, mining, and its own stable coin PowerCoin (PKoin). The project is a combination of the Finance 3.0 approach, cryptocurrency, and blockchain technology. It will tokenize assets and unlock the value of assets worldwide for investment and leveraging for finance, without selling them. The project roadmap includes developing a mining pool, innovation Center, high-performance Computing Data Center while acquiring assets such as renewable energy systems, real estate, financial instruments, intellectual property, digital and fiat currencies to back its hybrid stable coin PKoin. Currently listed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.